NBRV Nabriva Therapeutics plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBRV

Price (delayed)

$1.73

Market cap

$53.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.9

Enterprise value

$44.37M

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for ...

Highlights
Nabriva Therapeutics's EPS has soared by 63% YoY and by 5% from the previous quarter
Nabriva Therapeutics's revenue has surged by 61% YoY
The quick ratio has dropped by 63% year-on-year and by 26% since the previous quarter
NBRV's equity has plunged by 60% YoY and by 26% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nabriva.com
Peers: OVID

Key stats

What are the main financial stats of NBRV
Market
Shares outstanding
30.64M
Market cap
$53.01M
Enterprise value
$44.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
1.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.25
Earnings
Revenue
$35.63M
EBIT
-$45.48M
EBITDA
-$45.49M
Free cash flow
-$41.41M
Per share
EPS
-$1.9
Free cash flow per share
-$1.52
Book value per share
$0.96
Revenue per share
$1.3
TBVPS
$1.76
Balance sheet
Total assets
$48.24M
Total liabilities
$22.62M
Debt
$6.13M
Equity
$25.62M
Working capital
$25.92M
Liquidity
Debt to equity
0.24
Current ratio
2.2
Quick ratio
1.25
Net debt/EBITDA
0.19
Margins
EBITDA margin
-127.7%
Gross margin
50.9%
Net margin
-133.2%
Operating margin
-129.2%
Efficiency
Return on assets
-76%
Return on equity
-120%
Return on invested capital
-219.6%
Return on capital employed
-171%
Return on sales
-127.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBRV stock price

How has the Nabriva Therapeutics stock price performed over time
Intraday
0.29%
1 week
6.13%
1 month
3.59%
1 year
-84.74%
YTD
-8.47%
QTD
-8.47%

Financial performance

How have Nabriva Therapeutics's revenue and profit performed over time
Revenue
$35.63M
Gross profit
$18.13M
Operating income
-$46.04M
Net income
-$47.47M
Gross margin
50.9%
Net margin
-133.2%
Nabriva Therapeutics's revenue has surged by 61% YoY
The operating margin is up by 47% year-on-year
The company's net margin rose by 46% YoY
NBRV's gross profit is up by 31% YoY

Growth

What is Nabriva Therapeutics's growth rate over time

Valuation

What is Nabriva Therapeutics stock price valuation
P/E
N/A
P/B
1.8
P/S
1.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.25
Nabriva Therapeutics's EPS has soared by 63% YoY and by 5% from the previous quarter
NBRV's P/B is 89% below its 5-year quarterly average of 16.8 and 58% below its last 4 quarters average of 4.3
NBRV's equity has plunged by 60% YoY and by 26% from the previous quarter
The P/S is 99% below the 5-year quarterly average of 124.2 and 75% below the last 4 quarters average of 5.3
Nabriva Therapeutics's revenue has surged by 61% YoY

Efficiency

How efficient is Nabriva Therapeutics business performance
Nabriva Therapeutics's ROS has increased by 47% YoY
The return on invested capital rose by 30% year-on-year but it has declined by 9% since the previous quarter
The ROE is down by 26% since the previous quarter and by 22% year-on-year
Nabriva Therapeutics's ROA has decreased by 19% from the previous quarter and by 13% YoY

Dividends

What is NBRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBRV.

Financial health

How did Nabriva Therapeutics financials performed over time
The company's total assets is 113% higher than its total liabilities
The quick ratio has dropped by 63% year-on-year and by 26% since the previous quarter
The current ratio has dropped by 51% year-on-year and by 22% since the previous quarter
The company's debt is 76% lower than its equity
The debt to equity has soared by 85% YoY and by 14% from the previous quarter
NBRV's equity has plunged by 60% YoY and by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.